Alexandre Chagnon · 6 years ago
According to the Candesartan product monograph, Candesartan can sometimes be linked to more respiratory infections (5.1% of patients versus 3.8% of patients taking placebo). It is also possible, in very rare cases according to my research, that the side effect known to be associated with the Ramipril family, i.e. cough without infection, may be found in people taking candesartan (1.6% of patients, compared to 1.1% when taking placebo). These are therefore the possible effects of this drug on respiratory function.